Ann: Successful Placement and Board Changes, page-9

Here is a summary of new person to the board.

Dr Uvarov has significant experience in the healthcare industry with a particular focus on neuroscience. Dr Uvarov has started his career in biotechnology investments as equities analyst with Citigroup. He is a co-founding director of several publicly listed companies in Australia including clinical stage companies such as Dimerix (ASXXB), Actinogen Medical (ASX:ACW) and Neuroscientific Biopharmaceuticals (ASX:NSB). He was previously on the board of Imugene (ASX:IMU), a late-stage clinical oncology company.

The only company DXB has it's share price a lot higher 0.54. I hope he is not like the other DR that have been on the board.